SK bioscience, IDT Biologika, and Vaxxas will collaborate on a next-generation influenza vaccine development initiative.

Unlike traditional systemic vaccines, the mRNA vaccine under evaluation is designed to trigger a robust immune response directly at the site of influenza entry, with potential to reduce viral ...

International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public ...

SK Bioscience said Thursday it has secured its first European Union-backed vaccine development project alongside German subsidiary IDT Biologika, marking a key ...